Aptamer imaging with Cu-64 labeled AS1411: Preliminary assessment in lung cancer

Nuclear Medicine and Biology

Volumn 41, Issue 2, 2014, Pages 179-185

  Li, Junling ^a   Zheng, Huaiyu ^a   Bates, Paula J ^a   Malik, Tariq ^a   Li, Xiao Feng ^a   Trent, John O ^a   Ng, Chin K ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Aptamer; AS1411; Chelators; Cu 64; Oligonucleotide; PET

Indexed keywords

2 (4 ISOTHIOCYANATOBENZYL) 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; 2 (4 ISOTHIOCYANATOBENZYL) 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID OLIGONUCLEOTIDE AS1411 CU 64; 2 (4 ISOTHIOCYANATOBENZYL) 1,4,710 TETRAAZACYCLODODECANE TETRAACETIC ACID; 2 (4 ISOTHIOCYANATOBENZYL) 1,4,710 TETRAAZACYCLODODECANE TETRAACETIC ACID OLIGONUCLEOTIDE AS1411 CU 64; 4,11 BIS(CARBOXYMETHYL) 1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECANE; 4,11 BIS(CARBOXYMETHYL) 1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECANE OLIGONUCLEOTIDE AS1411 CU 64; APTAMER; CHELATING AGENT; COPPER 64; OLIGONUCLEOTIDE; RADIOPHARMACEUTICAL AGENT; TETRAXETAN; TETRAXETAN CU 64; TETRAXETAN OLIGONUCLEOTIDE AS1411 CU 64; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CHEMICAL INTERACTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TUMOR LEVEL; FEASIBILITY STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TEMPERATURE; INCUBATION TIME; INTERNALIZATION; ISOTOPE LABELING; LUNG CANCER; MICRO COMPUTER ASSISTED EMISSION TOMOGRAPHY; MOUSE; NONHUMAN;

APTAMER; AS1411; CHELATORS; CU-64; OLIGONUCLEOTIDE; PET;

ANIMALS; CELL LINE, TUMOR; COPPER RADIOISOTOPES; FEMALE; HUMANS; ISOTOPE LABELING; LUNG NEOPLASMS; MICE; OLIGODEOXYRIBONUCLEOTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84892998193     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.10.008     Document Type: Article

References (31)

1. Younes C.K., Boisgard R., Tavitian B. Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives. Curr Pharm Des 2002, 8(16):1451-1466.
2. Tavitian B. In vivo imaging with oligonucleotides for diagnosis and drug development. Gut 2003, 52(Suppl 4):iv40-iv47.
3. Bates P.J., Kahlon J.B., Thomas S.D., Trent J.O., Miller D.M. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 1999, 274(37):26369-26377.
4. Bates P.J., Laber D.A., Miller D.M., Thomas S.D., Trent J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 2009, 86(3):151-164.
5. Soundararajan S., Chen W., Spicer E.K., Courtenay-Luck N., Fernandes D.J. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res 2008, 68(7):2358-2365.
6. Wadas T.J., Wong E.H., Weisman G.R., Anderson C.J. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des 2007, 13(1):3-16.
7. Li W.P., Lewis J.S., Kim J., Bugaj J.E., Johnson M.A., Erion J.L., et al. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. Bioconjug Chem 2002, 13(4):721-728.
8. Boswell C.A., Sun X., Niu W., Weisman G.R., Wong E.H., Rheingold A.L., et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 2004, 47(6):1465-1474.
9. Wu Y., Zhang X., Xiong Z., Cheng Z., Fisher D.R., Liu S., et al. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med 2005, 46(10):1707-1718.
10. Li J., Trent J.O., Bates P.J., Ng C.K. Factors affecting the labeling yield of F-18-labeled AS1411. J Labelled Comp Radiopharm 2007, 50:1255-1259.
11. 64Cu-labeled RGD peptide. Bioconjug Chem 2004, 15(1):41-49.
12. Ni X., Castanares M., Mukherjee A., Lupold S.E. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 2011, 18(27):4206-4214.
13. Keefe A.D., Pai S., Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010, 9(7):537-550.
14. Hicke B.J., Stephens A.W., Gould T., Chang Y.F., Lynott C.K., Heil J. Tumor targeting by an aptamer. J Nucl Med 2006, 47(4):668-678.
15. 18F]fluorobenzoate (S18FB). J Labelled Comp Radiopharm 2006, 49:1213-1221.
16. 18F]-labelling of aliphatic compounds in high yields via aminopolyether-supported nucleophilic substitution. J Labelled Comp Radiopharm 1986, 23(5):467-477.
17. 18F for in vivo PET imaging. J Labelled Comp Radiopharm 1997, 39(4):319-330.
18. 18F-labelled pyridine-based alkylating agent for high yield oligonucleotide conjugation. Appl Radiat Isot 2009, 67(9):1670-1675.
19. Sun X., Fang H., Li X., Rossin R., Welch M.J., Taylor J.S. MicroPET imaging of MCF-7 tumors in mice via unr mRNA-targeted peptide nucleic acids. Bioconjug Chem 2005, 16(2):294-305.
20. Wu A.M., Yazaki P.J., Tsai S., Nguyen K., Anderson A.L., McCarthy D.W., et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A 2000, 97(15):8495-8500.
21. 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med 2012, 53(1):138-145.
22. 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med 2007, 48(1):64-72.
23. 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 2007, 48(8):1327-1337.
24. 64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 2007, 104(30):12462-12467.
25. Smith S.V. Molecular imaging with copper-64 in the drug discovery and development arena. Expert Opin Drug Discov 2007, 2(5):659-672.
26. 64Cu-labeled triphenylphosphonium cations. J Med Chem 2008, 51(10):2971-2984.
27. Rusckowski M., Qu T., Gupta S., Ley A., Hnatowich D.J. A comparison in monkeys of (99m)Tc labeled to a peptide by 4 methods. J Nucl Med 2001, 42(12):1870-1877.
28. Reyes-Reyes E.M., Teng Y., Bates P.J. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res 2010, 70(21):8617-8629.
29. Soundararajan S., Wang L., Sridharan V., Chen W., Courtenay-Luck N., Jones D., et al. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol Pharmacol 2009, 76(5):984-991.
30. Sun X., Wuest M., Weisman G.R., Wong E.H., Reed D.P., Boswell C.A., et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem 2002, 45(2):469-477.
31. Mongelard F., Bouvet P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther 2010, 12(1):107-114.